| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Knowles Julius | Director | C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON | /s/ Keith Regnante, Attorney-in-Fact | 18 Dec 2025 | 0001808365 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | KROS | Common Stock | Disposed to Issuer | $3,399,604 | -191,527 | -56% | $17.75 | 150,047 | 21 Nov 2025 | See footnote | F1, F2 |
| transaction | KROS | Common Stock | Disposed to Issuer | $2,316,268 | -130,494 | -56% | $17.75 | 102,233 | 21 Nov 2025 | See footnote | F1, F3 |
| holding | KROS | Common Stock | 6,441 | 21 Nov 2025 | Direct |
| Id | Content |
|---|---|
| F1 | Represents shares tendered and accepted for purchase by the Issuer in a cash tender offer commenced by the Issuer on October 20, 2025. The Issuer announced the final results of the tender offer on November 20, 2025. |
| F2 | The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. |
| F3 | The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. |